Split History
ETFs Holding ATNM »    ATNM Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Actinium Pharmaceuticals is a clinical-stage, biopharmaceutical company. Co.'s clinical programs are focused on the following primary areas: targeted conditioning prior to a cell or gene therapy procedure and therapeutics, either in combination with other agents or as a monotherapy. Co.'s primary CD45 targeted conditioning product candidate is Iomab-B, which uses high doses of Iodine-131 to achieve myeloablative conditioning prior to a bone marrow transplant. Co.'s CD33 program is evaluating the clinical utility of an Antibody Radiation-Conjugates comprised of the anti-CD33 monoclonal antibody lintuzumab linked to the potent alpha-emitting radioisotope Actinium-225. According to our ATNM split history records, Actinium Pharmaceuticals has had 1 split.
ATNM split history picture
Actinium Pharmaceuticals (ATNM) has 1 split in our ATNM split history database. The split for ATNM took place on August 11, 2020. This was a 1 for 30 reverse split, meaning for each 30 shares of ATNM owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 33.3333333333333 share position following the split.

When a company such as Actinium Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the ATNM split history from start to finish, an original position size of 1000 shares would have turned into 33.3333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Actinium Pharmaceuticals shares, starting with a $10,000 purchase of ATNM, presented on a split-history-adjusted basis factoring in the complete ATNM split history. ATNM split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 12/27/2012
End date: 06/23/2021
Start price/share: $45.00
End price/share: $7.78
Dividends collected/share: $0.00
Total return: -82.71%
Average Annual Total Return: -18.67%
Starting investment: $10,000.00
Ending investment: $1,729.79
Years: 8.49
Date Ratio
08/11/20201 for 30
ATNM is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ATOS Split History
ATRC Split History
ATRI Split History
AVEO Split History
AVGR Split History
AVXL Split History
AYTU Split History
AZN Split History
BAX Split History
BCR Split History

Trisura Group Ltd. (TSU.CA)
BetaPro NASDAQ-100 2x Daily Bull ETF (HQU)
BetaPro S&P 500 2x Daily Bull ETF (HSU)
BetaPro S&P/TSX Capped Energy 2x Daily Bull ETF (HEU)
BetaPro S&P/TSX Capped Financials 2x Daily Bull ETF (HFU)
BetaPro S&P/TSX 60 2x Daily Bull ETF (HXU)
BetaPro Crude Oil Leveraged Daily Bull ETF (HOU)
Horizons Big Data & Hardware Index ETF (HBGD.U)
Horizons Big Data & Hardware Index ETF (HBGD)
Horizons NASDAQ-100 Index ETF (HXQ.U)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ATNM Insider Buying

ATNM Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.